Journal
CLINICAL CANCER RESEARCH
Volume 28, Issue 14, Pages 3156-3169Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-21-2563
Keywords
-
Categories
Funding
- Lou and Jean Malnati Brain Tumor Institute [P30 CA060553, 5DP5OD021356-05, 1R01CA245969-01A1]
- Moceri Family Foundation and developmental funds from The Robert H. Lurie Comprehensive Cancer Center [P50CA221747]
- Higher Education Institutional Excellence Programme of the Ministry for Innovation and Technology in Hungary [P30CA060553]
- NCI CCSG [2020-4.1.1.-TKP2020]
- NCI [P30 CA060553]
- [P30-CA060553]
Ask authors/readers for more resources
By analyzing genome-wide CRISPR knockout screen results and patient data, researchers identified endoplasmic reticulum protein SSR3 as a potential predictive biomarker for susceptibility to Paclitaxel in breast cancer and glioblastoma.
Purpose: Paclitaxel (PTX) is one of the most potent and com-monly used chemotherapies for breast and pancreatic cancer. Several ongoing clinical trials are investigating means of enhancing delivery of PTX across the blood-brain barrier for glioblastomas. Despite the widespread use of PTX for breast cancer, and the initiative to repurpose this drug for gliomas, there are no predictive biomarkers to inform which patients will likely benefit from this therapy. Experimental Design: To identify predictive biomarkers for susceptibility to PTX, we performed a genome-wide CRISPR knockout (KO) screen using human glioma cells. The genes whose KO was most enriched in the CRISPR screen underwent further selection based on their correlation with survival in the breast cancer patient cohorts treated with PTX and not in patients treated with other chemotherapies, a finding that was validated on a second independent patient cohort using progres-sion-free survival. Results: Combination of CRISPR screen results with out-comes from patients with taxane-treated breast cancer led to the discovery of endoplasmic reticulum (ER) protein SSR3 as a putative predictive biomarker for PTX. SSR3 protein levels showed positive correlation with susceptibility to PTX in breast cancer cells, glioma cells, and in multiple intracranial glioma xenografts models. KO of SSR3 turned the cells resistant to PTX while its overexpression sensitized the cells to PTX. Mechanistically, SSR3 confers susceptibility to PTX through regulation of phosphorylation of ER stress sensor IRE1z. Conclusions: Our hypothesis generating study showed SSR3 as a putative biomarker for susceptibility to PTX, warranting its prospective clinical validation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available